Katsumi Doh-Ura[Author] - Search Results

Year	Number of Results
2001	1
2002	3
2003	6
2004	7
2005	1
2006	5
2007	8
2008	1
2009	5
2010	3
2011	5
2012	2
2013	1
2014	1
2015	4
2016	1
2017	3
2018	1
2019	4
2020	2
2021	2
2022	3
2023	3
2024	0

1

Therapeutic development of polymers for prion disease.

Teruya K, Doh-Ura K. Teruya K, et al. Among authors: doh ura k. Cell Tissue Res. 2023 Apr;392(1):349-365. doi: 10.1007/s00441-022-03604-1. Epub 2022 Mar 21. Cell Tissue Res. 2023. PMID: 35307792 Review.

2

Insights from Therapeutic Studies for PrP Prion Disease.

Teruya K, Doh-Ura K. Teruya K, et al. Among authors: doh ura k. Cold Spring Harb Perspect Med. 2017 Mar 1;7(3):a024430. doi: 10.1101/cshperspect.a024430. Cold Spring Harb Perspect Med. 2017. PMID: 27836910 Free PMC article. Review.

3

Amyloid-binding compounds and their anti-prion potency.

Teruya K, Doh-ura K. Teruya K, et al. Among authors: doh ura k. Curr Top Med Chem. 2013;13(19):2522-32. doi: 10.2174/15680266113136660178. Curr Top Med Chem. 2013. PMID: 24059333 Review.

4

Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer's disease.

Ali T, Klein AN, McDonald K, Johansson L, Mukherjee PG, Hallbeck M, Doh-Ura K, Schatzl HM, Gilch S. Ali T, et al. Among authors: doh ura k. J Neuroinflammation. 2023 Jul 28;20(1):177. doi: 10.1186/s12974-023-02858-y. J Neuroinflammation. 2023. PMID: 37507761 Free PMC article.

5

Amyloidophilic compounds for prion diseases.

Teruya K, Kawagoe K, Kimura T, Chen CJ, Sakasegawa Y, Doh-ura K. Teruya K, et al. Among authors: doh ura k. Infect Disord Drug Targets. 2009 Feb;9(1):15-22. doi: 10.2174/1871526510909010015. Infect Disord Drug Targets. 2009. PMID: 19200011 Review.

6

Activities of curcumin-related compounds in two cell lines persistently infected with different prion strains.

Teruya K, Iwabuchi S, Watanabe Y, Tsuchida R, Watanabe-Matsui M, Konno H, Doh-Ura K. Teruya K, et al. Among authors: doh ura k. Biochim Biophys Acta Gen Subj. 2022 Apr;1866(4):130094. doi: 10.1016/j.bbagen.2022.130094. Epub 2022 Jan 19. Biochim Biophys Acta Gen Subj. 2022. PMID: 35065183

7

Combination of Styrylbenzoazole Compound and Hydroxypropyl Methylcellulose Enhances Therapeutic Effect in Prion-Infected Mice.

Teruya K, Oguma A, Iwabuchi S, Nishizawa K, Doh-Ura K. Teruya K, et al. Among authors: doh ura k. Mol Neurobiol. 2023 Dec 20. doi: 10.1007/s12035-023-03852-4. Online ahead of print. Mol Neurobiol. 2023. PMID: 38114760

8

[Innovation of therapeutics and prophylaxis for prion diseases].

Doh-ura K. Doh-ura K. Rinsho Shinkeigaku. 2009 Nov;49(11):946-8. doi: 10.5692/clinicalneurol.49.946. Rinsho Shinkeigaku. 2009. PMID: 20030256 Review. Japanese.

9

Polymorphisms in glia maturation factor β gene are markers of cellulose ether effectiveness in prion-infected mice.

Teruya K, Oguma A, Arai K, Nishizawa K, Iwabuchi S, Watanabe-Matsui M, Sakasegawa Y, Schätzl H, Gilch S, Doh-Ura K. Teruya K, et al. Among authors: doh ura k. Biochem Biophys Res Commun. 2021 Jun 30;560:105-111. doi: 10.1016/j.bbrc.2021.04.116. Epub 2021 May 10. Biochem Biophys Res Commun. 2021. PMID: 33984767

10

Combining autophagy stimulators and cellulose ethers for therapy against prion disease.

Abdulrahman BA, Tahir W, Doh-Ura K, Gilch S, Schatzl HM. Abdulrahman BA, et al. Among authors: doh ura k. Prion. 2019 Jan;13(1):185-196. doi: 10.1080/19336896.2019.1670928. Prion. 2019. PMID: 31578923 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

66 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year